← All trials
NCT06366464
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2024
- Primary completion
- Jul 31, 2026
- Completion date
- Jul 31, 2027
- First posted
- Apr 16, 2024
- Last posted
- Nov 8, 2024
- Enrollment
- 134
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harmony Biosciences, LLCLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.